The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy

[1]  G. Rosner,et al.  Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors , 2022, JCO precision oncology.

[2]  P. Kasi,et al.  Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Y. Bang,et al.  Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  L. Bucheit,et al.  Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer , 2022, Journal for ImmunoTherapy of Cancer.

[5]  Kai Zhang,et al.  ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors , 2022, BMC Medicine.

[6]  Lisa Kim,et al.  Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting , 2022, Oncoimmunology.

[7]  A. Lovejoy,et al.  Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC , 2022, Journal for ImmunoTherapy of Cancer.

[8]  Ying Cheng,et al.  On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial , 2022, Molecular cancer.

[9]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[10]  Yoon-Koo Kang,et al.  Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. , 2022, The Lancet. Oncology.

[11]  E. Oki,et al.  80P Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN , 2021, Annals of Oncology.

[12]  L. Shen,et al.  Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis , 2021, Frontiers in Oncology.

[13]  Y. Chae,et al.  Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB , 2021, Journal for ImmunoTherapy of Cancer.

[14]  A. Cercek,et al.  TMB cutoffs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in Keynote-061. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Ajani,et al.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial , 2021, The Lancet.

[16]  C. Fuchs,et al.  Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  E. Sokol,et al.  Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA). , 2021, Journal of Clinical Oncology.

[18]  T. Zander,et al.  Optimized PD-L1 scoring of gastric cancer , 2021, Gastric Cancer.

[19]  D. Gandara,et al.  ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy , 2021, JCO precision oncology.

[20]  F. Lordick,et al.  Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm , 2021, Nature Reviews Clinical Oncology.

[21]  E. Jonasch,et al.  High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[23]  A. Stenzinger,et al.  Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. , 2020, Cancer discovery.

[24]  Fenghua Wang,et al.  The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors , 2020, Molecular cancer.

[25]  Ash A. Alizadeh,et al.  Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition , 2020, Cell.

[26]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[27]  Y. Bang,et al.  Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. , 2020, JAMA oncology.

[28]  Katherine I Zhou,et al.  Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy , 2020, Clinical Cancer Research.

[29]  Song Wu,et al.  Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. , 2020, Cancer discovery.

[30]  I. Chau,et al.  Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer , 2020, ESMO Open.

[31]  L. Shen,et al.  Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer , 2020, Journal for ImmunoTherapy of Cancer.

[32]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[33]  V. Thorsson,et al.  Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  A. Stenzinger,et al.  Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project , 2020, Journal for ImmunoTherapy of Cancer.

[35]  P. Therasse.  Immune-Related Response Criteria , 2020, Definitions.

[36]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[37]  De-Hua Wu,et al.  Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer , 2019, Clinical Cancer Research.

[38]  M. J. van de Vijver,et al.  Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma , 2019, International journal of cancer.

[39]  Catalin C. Barbacioru,et al.  Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel , 2019, Clinical Cancer Research.

[40]  Y. Jiang,et al.  Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  A. Ohtsu,et al.  Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer , 2019, Journal of Immunotherapy for Cancer.

[42]  M. Speicher,et al.  Current and future perspectives of liquid biopsies in genomics-driven oncology , 2018, Nature Reviews Genetics.

[43]  Joon-Oh Park,et al.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.

[44]  Kazuhiro Yoshida,et al.  Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial , 2018, The Lancet.

[45]  C. Paweletz,et al.  Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies , 2018, Clinical Cancer Research.

[46]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[47]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[48]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[49]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[50]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[51]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[52]  J. Paul,et al.  New Dimensions , 2011 .

[53]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[54]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[55]  Jeffrey James,et al.  An emerging paradigm , 2004 .